Overview
According to the American Cancer Society, prostate cancer (PCA) is the most common type of cancer found in American men. Currently, the major therapy for PCA in both primary and advanced stages is androgen deprivation. This treatment exerts its effects on target tissue by either blocking androgen synthesis or preventing binding of androgens to the androgen receptor (AR). However, one of the major downfalls to this method of treatment involves resistance development. The present technology relates to a new class of small molecules and the promise they show as a therapeutic approach to treat PCA by decreasing androgen synthesis and/or androgen receptor expression or function.
Applications
-Cancer therapies -Development of novel cancer therapies
Advantages
-Offers novel approach for the prevention and treatment of PCA. -Involves the use of novel compounds that have therapeutic promise.
Stage of Development
Small molecules possessing anti-cancer properties have been identified.
R&D Required
Studies are required to demonstrate efficacy and safety prior to use in human subjects.
Licensing Potential
UMB seeks partners for commercialization.
Contact Info
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: [email protected]
Phone: (410) 706-2380